Hormonal
Central insulin resistance is a common pathophysiological mechanism linking Type 2 Diabetes and Alzheimer's Disease, contributing to cognitive decline and metabolic dysregulation.
If you have Type 2 Diabetes, managing your blood sugar is also about protecting your brain. Central insulin resistance is a key link between diabetes and cognitive decline (like Alzheimer's). Prioritizing insulin sensitivity through lifestyle or medication may help preserve cognitive function, as the brain relies on proper insulin signaling for memory and metabolic health.
Advances in the knowledge of preclinical AD and T2DM may be a major stimulus for the development of treatment for preventing the pathogenic events of these disorders, mainly those focused on reducing brain insulin resistance, which is seems to be a common ground for both pathological entities.
Why this rating
The paper is a comprehensive review citing multiple studies on insulin receptors, transport, and signaling in the brain.
Source
Insulin in the Brain: Its Pathophysiological Implications for States Related with Central Insulin Resistance, Type 2 Diabetes and Alzheimer’s Disease
Enrique Blázquez et al. · Frontiers in Endocrinology · 2014
DOI 10.3389/fendo.2014.00161
More from this paper
- Insulin crosses the blood-brain barrier via a saturable transport system, and this transport is impaired in conditions like obesity, diabetes, and aging.Good
- Insulin in the brain acts as an anorexigenic hormone, regulating food intake and energy expenditure through hypothalamic receptors, distinct from its peripheral anabolic effects.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →